Xbrane Biopharma Bilan de santé

Santé financière contrôle des critères 3/6

Xbrane Biopharma possède un total de capitaux propres de SEK260.1M et une dette totale de SEK124.2M, ce qui porte son ratio d'endettement à 47.7%. Son actif total et son passif total sont SEK839.7M et de SEK579.5M.

Informations clés

47.7%

Ratio d'endettement

SEK 124.18m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 30.59m
Fonds propres	SEK 260.15m
Total du passif	SEK 579.52m
Total des actifs	SEK 839.67m

Mises à jour récentes de la santé financière

Recent updates

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Sep 30

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Aug 05

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Jun 04

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Nov 05

Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)

Mar 24

Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings

Mar 02

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

Feb 10

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Jan 12

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de XBRANE ( SEK639.0M ) dépassent ses passifs à court terme ( SEK474.2M ).

Passif à long terme: Les actifs à court terme de XBRANE ( SEK639.0M ) dépassent ses passifs à long terme ( SEK105.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de XBRANE ( 36% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de XBRANE est passé de 0.02% à 47.7% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: XBRANE dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: XBRANE dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 31.5 % chaque année

Xbrane Biopharma Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Recent updates

New major risk - Financial position

Xbrane Biopharma AB (publ), Annual General Meeting, May 05, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2025 Results on May 08, 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Xbrane Provides Update from Scientific Advice with US FDA on Xdivane™ (Opdivo® Biosimilar Candidate)

Consensus EPS estimates upgraded to kr0.095 loss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

First quarter 2024 earnings: Revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Consensus EPS estimates fall by 35%

New minor risk - Financial position

New major risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Market cap size

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) Focuses on Development Portfolio and Introduces A Cost-Savings Scheme

Xbrane Biopharma AB (publ) to Report First Half, 2024 Results on Jul 17, 2024

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Price target increased by 13% to kr253

New major risk - Financial position

Chief Executive Officer recently bought kr150k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr817k worth of stock

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Feb 29, 2024

CFO & Head of Investor Relations recently bought kr236k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 15%

Now 22% undervalued

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 04, 2023

Insider recently bought kr156k worth of stock

Chief Executive Officer recently bought kr175k worth of stock

Xbrane Provides an Update on Ranibizumab Biosimilar Candidate FDA Filing

Forecast breakeven date pushed back to 2024

Price target increased to kr173

STADA Arzneimittel AG and Xbrane Biopharma AB Secures EU Approval for Ximluci (Ranibizumab) Biosimilar Referencing Lucentis

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report First Half, 2023 Results on Aug 31, 2023

STADA Arzneimittel AG and Xbrane Biopharma AB (publ) Announce European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion for Ximluci

Xbrane Biopharma AB (publ), Annual General Meeting, May 04, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 31, 2023

Xbrane Biopharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 31, 2023

Xbrane Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Chief Executive Officer recently sold kr1.0m worth of stock

An unknown buyer acquired an unknown minority stake in Xbrane Biopharma AB (publ) (OM:XBRANE) from Martin Amark and Siavash Bashiri.

Head of Regulatory Affairs recently bought kr104k worth of stock

Chief Technology Officer recently bought kr699k worth of stock

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Xbrane Biopharma AB (publ) Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Price target increased to kr235

Chief Executive Officer recently sold kr496k worth of stock

Xbrane Biopharma AB (Publ) Announces Positive Top-Line Results from the Pivotal Phase III Equivalence Trial for Xlucane™ - A Biosimilar Candidate to Lucentis

Xbrane Biopharma AB (publ)(OM:XBRANE) dropped from OMX Nordic Small Cap Index

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Consensus EPS estimates increase to -kr9.83

Forecast to breakeven in 2023

Head of Regulatory Affairs recently bought kr125k worth of stock